Newly merged RNAi firm starts to bed down
This article was originally published in Scrip
Executive Summary
The signing of a partnership deal is not the only measure by which the merger of Silence Therapeutics and Intradigm Therapeutics will be judged a success, the new company's chief executive Dr Philip Haworth told Scrip.